Current Status and Clinical Developments in Lung Cancer: What to Expect from Emerging Drugs?
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 March 2025 | Viewed by 4385
Special Issue Editor
Interests: epigenetic modulation in solid tumors; lung cancer; next generation technologies in molecular biology; predictive oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer, small cell lung cancer and non-small cell lung cancer are the leading causes of cancer-related death. Most of the time, the symptoms appear late; thus, the diagnosis of lung cancer patients occurs at an advanced stage. The treatment of patients with lung cancer includes multidisciplinary approaches that are based on surgical practice, such as chemotherapy, radiotherapy, targeted therapies, and immunotherapy, which largely improve the quality of life and survival rates.
For this reason, this Special Issue will embrace innovative treatments, as well as immunotherapy drugs and molecular targeted therapies, that simplify the comprehension of the molecular biology of lung cancer in the era of personalized medicine, with the aid of diagnostic and therapeutic technologies and rational drug design.
Dr. Federico Pio Fabrizio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- immunotherapy
- immune checkpoint inhibitors (ICIs)
- target therapy
- tyrosine kinase inhibitors (TKIs)
- cancer biomarkers